FDA Proposed Rule Would Streamline cGMPs for PET Drugs

Drug GMP Report

The FDA has issued a proposed rule that would streamline cGMPs for the manufacture of positron emission tomography (PET) drugs, making it easier for drug producers to comply with federal quality requirements.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $10.00